Cargando…

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria

OBJECTIVE: Efavirenz (EFV) use is associated with neuropsychiatric side effects, which may include poor neurocognitive performance. We evaluated single nucleotide polymorphisms in genes that contribute to EFV pharmacokinetics and examined them in association with EFV concentrations in plasma and hai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nwogu, Jacinta N., Gandhi, Monica, Owen, Andrew, Khoo, Saye H., Taiwo, Babafemi, Olagunju, Adeniyi, Berzins, Baiba, Okochi, Hideaki, Tallerico, Regina, Robertson, Kevin, Babalola, Chinedum P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462442/ https://www.ncbi.nlm.nih.gov/pubmed/34115651 http://dx.doi.org/10.1097/QAD.0000000000002984

Ejemplares similares

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria
por: Nwogu, Jacinta N., et al.
Publicado: (2022)

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals
por: Nwogu, Jacinta Nwamaka, et al.
Publicado: (2016)

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
por: Olagunju, Adeniyi, et al.
Publicado: (2022)

Similar changes in neuropsychological functioning in english and spanish speaking HIV patients
por: Akpa, Onoja, et al.
Publicado: (2018)

Brain computed tomography perfusion analysis in HIV-seropositive adults with and without neurocognitive impairment in Nigeria: outcomes and challenges of a pilot study
por: Ogbole, Godwin, et al.
Publicado: (2023)

Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle‐cell disease patients and healthy controls in Nigeria
por: Adejumo, Olufunmilayo E., et al.
Publicado: (2016)

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants
por: Mollan, Katie R, et al.
Publicado: (2017)

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study
por: Buzibye, Allan, et al.
Publicado: (2023)

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis
por: Duwal, Sulav, et al.
Publicado: (2019)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
por: Dickinson, Laura, et al.
Publicado: (2015)

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
por: Siccardi, Marco, et al.
Publicado: (2013)

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs
por: Waitt, Catriona, et al.
Publicado: (2018)

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies
por: Atoyebi, Shakir Adeyinka, et al.
Publicado: (2019)

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
por: Leger, Paul, et al.
Publicado: (2018)

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC–MS/MS
por: Waitt, Catriona, et al.
Publicado: (2017)

Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment
por: Srinivas, Nithya, et al.
Publicado: (2019)

A brief review of the genetics and pharmacogenetics of opioid use disorders
por: Berrettini, Wade
Publicado: (2017)

Successful Implementation Strategies in iCARE Nigeria—A Pilot Intervention with Text Message Reminders and Peer Navigation for Youth Living with HIV
por: Ahonkhai, Aima A., et al.
Publicado: (2023)

365. Neurocognitive Function Change after Switching from Efavirenz to Rilpivirine in HIV-Infected Adults: A Randomized Control Trial
por: Kaewpoowat, Quanhathai, et al.
Publicado: (2019)

Lead and Cadmium Levels in Residential Soils of Lagos and Ibadan, Nigeria
por: Adeyi, Adebola A., et al.
Publicado: (2017)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
por: Seden, Kay, et al.
Publicado: (2018)

Bisphenol-A (BPA) in Foods commonly consumed in Southwest Nigeria and its Human Health Risk
por: Adeyi, Adebola A., et al.
Publicado: (2019)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
por: Cummins, Nathan W., et al.
Publicado: (2015)

High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology
por: Musa, Jonah, et al.
Publicado: (2014)

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
por: Mukonzo, Jackson K, et al.
Publicado: (2013)

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
por: Scarsi, Kimberly, et al.
Publicado: (2014)

Remote ischemic preconditioning protects neurocognitive function of rats following cerebral hypoperfusion
por: Xu, Tao, et al.
Publicado: (2011)

Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa—A Retrospective Case Series
por: Hammond, Charles K., et al.
Publicado: (2019)

High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients
por: Hakkers, Charlotte S., et al.
Publicado: (2020)

Evaluation of the iCARE Nigeria Pilot Intervention Using Social Media and Peer Navigation to Promote HIV Testing and Linkage to Care Among High-Risk Young Men: A Nonrandomized Controlled Trial
por: Garofalo, Robert, et al.
Publicado: (2022)

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
por: Ochanda, Perez Nicholas, et al.
Publicado: (2022)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores)
por: Branco, Claudia C, et al.
Publicado: (2009)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Adaptation of evidence-based approaches to promote HIV testing and treatment engagement among high-risk Nigerian youth
por: Kuhns, Lisa M., et al.
Publicado: (2021)

No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study)
por: Kling, Kendall D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pdb7t7urv2ugpc15bino63pru4